Regence: Biosimilar Adoption Reduces $37 Million in Annual Spending

November 28, 2022

Regence found that implementing strategies to increase its biosimilar adoption rate reduced spending on specialty drugs by $37 million annually. The organization is the latest example of how biosimilar use has contributed to significant savings.

What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars
VOLTAIRE-X Findings in Patients With Chronic Plaque Psoriasis Supported Interchangeability
The Top 5 Biosimilar Articles for the Week of November 21
Alvotech Snags Australian Approval for Adalimumab Biosimilar